Gemcitabine elaidate

Drug Profile

Gemcitabine elaidate

Alternative Names: CO-1.01; CO-101; CP-4126; Gemcitabine 5'-elaidic acid ester

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clavis Pharma
  • Developer Clavis Pharma; Clovis Oncology
  • Class Antineoplastics; Deoxyribonucleosides; Esters; Pyrimidine nucleosides
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in United Kingdom (IV)
  • 15 Feb 2013 Discontinued - Phase-I for Non-small cell lung cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top